Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423)

Volume 3 Issue 10 October 2019

Review Article

The Effectiveness of Selected Saudi Medicinal Plants in the Management of Diabetes Mellitus: A Review

Isam M Abu Zeid[1,2]*

[1]*Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, Saudi Arabia*

[2]*Princess Dr. Najla Bint Saud Al Saud Center for Excellence Research in Biotechnology, King Abdulaziz University, Jeddah, Saudi Arabia*

***Corresponding Author:** Isam M Abu Zeid, Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, Saudi Arabia.

Received: August 27, 2019; **Published:** September 05, 2019

DOI: 10.31080/ASPS.2019.03.0391

Abstract

Diabetes mellitus is a chronic metabolic illness which is distinguished by a long-term hyperglycaemic condition. In so many communities it is devastatingly inflicts a major socio economic problem in humans, especially to the adversely attacked patients. Saudi Arabia is known to be one of the top countries worldwide with the sharpest penetration and high prevalence of diabetes. The conventional treatment of diabetes involves a sustained reduction of homeostatic blood glucose levels using different synthetic drugs. Medicinal plants are natural sources, they have fewer side effects, and they offer evidence for the synthesis of novel and improved medicines for the treatment of diabetes. This review provides useful information and analyzed the results reported in the literature related to the hypoglycemic effect of selected Saudi medicinal plants that are potentially and scientifically validated.

Keywords: Diabetes; Saudi Arabia; Prevalence; Medicinal Plants

Introduction

Diabetes mellitus (DM) is a chronic metabolic illness which is distinguished by a long-term hyperglycaemic condition [1,2]. According to contemporary and universally trajectory of DM disease and by the year 2040, there will be about 642 million diabetic subjects [3]. In so many communities it is devastatingly inflicts a major socio economic problem in humans, especially to the adversely attacked patients. As a metabolic disorder, DM is the underlying precipitant of many crucial debilitating diseases especially the nephropathy, peripheral polyneuropathy, retinopathy, atherosclerosis, peripheral arterial disorder, coronary artery disease, and cerebrovascular disorder [4-9]. The prevalence of end stage renal disease is higher amongst patients with DM [10].

The financial burden related to diabetes resulted mainly from both the expenses of medical treatment as well as the expensive toll of reduced efficiency linked to diabetes-associated morbidity and mortality [11]. Currently, different therapeutic approaches are enacted and applied to suppress and ultimately control the disease using synthetic anti-diabetic drugs in addition to the strict life style modification. Unfortunately, most of the available anti-diabetic drugs are associated with many adverse drug reactions, costly and not readily affordable to the majority of the affected population [12]. Medicinal plants and the potential alternative remedies are safer, active, and inexpensive options when compared to the oral hypoglycaemic agents [13]. The main active constituents of these antidiabetic herbs that engaged to have hypoglycaemic effect are mostly glycosides, alkaloids, terpenoids, flavonoids, carotenoids and saponins [14-17]. Many medicinal plants extracts have shown their ability to treat DM by stimulating the pancreatic beta cells to secrete insulin both *in vivo* and *in vitro* studies [18, 19]. Thus, the objectives of this review were undertaken to validate the base line

data of traditional use of selected Saudi medicinal plants in the control and treatment of diabetes which would provide an alternative lucrative platform for a scientific basis for the evidently subsequent standardization and commercialization of these medicinal plants as antihyperglycemic natural products.

Global prevalence and incidence of DM

Type-1 DM outlines approximately 10% of all patients with DM, attacking nearly 20 million persons worldwide [20,21]. Type-2 DM is the dominant type of DM and represent 90% of DM cases [22-24]. Globally, by 2030, there will be about 439 million persons with DM [25,26]. The number is supposed to rise to 642 million by 2040 [25]. Worldwide, the high incidence of DM is expected to be present in the Middle East and North Africa region [27]. Saudi Arabia is among the top 10 countries mostly affected by DM with 31.6% prevalence [28-30].

Prevalence and economic burden of diabetes in Saudi Arabia

From the geographical and geological point of view it shows that the KSA without comparison is the largest country in the Arabian Peninsula and in the Middle East comprising alone about four-fifth of the Arabian Peninsula which has the population of more than 33.3 million citizens [31]. Saudi is known to be one of the top countries worldwide with the sharpest penetration and high prevalence of diabetes [25,30]. In Saudi Arabia, approximately 4004 participants out of 16917 were confirmed to be diabetics [32]. Moreover, the incidence of DM was more predominant amongst Saudis females in the civilized modern societies [27]. Type I DM is the most widespread among the young individuals that places KSA in the 5th position around the world in penetration levels in children [33]. In terms of the total population of children with IDDM, the position of the country is 7th in world ranking [33]. In terms of town versus rural societies, the prevalence is 25% vis-à-vis 19.5%, respectively, from the data of 2014 [34]. In a contemporary recent report the prevalence of diabetes in Saudi Arabia was found to be about 14.8% among men and 11.7% among women leading to (53.0% and 47.8% among men and women of age 55–64 years, respectively) which sounds the alarm and raised the awareness that 40.2% of these men and 48.4% of women were previously undiagnosed for diabetes. Moreover, 22.9% of diabetic men and 23.4% of women were being treated, but their blood glucose levels remained uncontrolled [35].

Globally Diabetes as a scary formidable menace it imposes a large economic toll on the afflicted individuals, the national healthcare systems and evidently the economy of all countries. Economically, KSA takes a great chunk of its health budget on diabetes. A substantial percentage the country's spending on the health sector goes into the control of the disease. The 2010 allocation of $ 0.9 billion represented a significant margin of the over 9 billion dollars the health sector spent in that year [28]. The overall monetary cost is estimated to be skyrocketing reaching about $6.5 billion by the 2020 reflecting an increase of $5.6 billion (or 7 times higher than the cost in 2010) within the next 10 years [28]. Although diabetes imposes a large economic burden on national healthcare budget the estimated medical healthcare expenditures attributed to diabetes including an array of the indirect costs associated with diabetes. These costs comprise a wide spectrum such as absenteeism, lost productivity from disease-related complications, unemployment due to disability and early mortality by the disease. The spectre of ddiabetes social cost is aggravated by affected individuals pain, sufferings and unprofessional care provided by caregivers in addition to healthcare systems administrative costs, furthered by the cost of medications, clinician training programs, initiatives research and infrastructural development [28,32].

Adverse effect of synthetic anti-diabetic drugs

Diabetes mellitus causes many complications of kidney and heart ailments, which resulted in the obstruction of patients to perform work hence it does constitute an added economic burden to the society. The economic toll associated with DM is substantiated by twin factors embodying the direct costs of medical care as well as indirect costs of an overall diminished productivity evidently tied to diabetic ailments that emanate from morbidity and mortality [11]. There are several synthetic drugs categories that are involved in the treatment of DM including, biguanides (metformin), sulfonylureas (glyburide), meglitinides (Nate glinide), thiazolidinediones (pioglitazone), alpha-glucosidase inhibitors (acarbose), incretin-based therapies (exenatide) and dipeptidyl-peptidase IV (DDP-4) inhibitors (sitagliptin) [36-38].

The use of the synthetic drugs in the treatment of DM is accompanied with diverse array of side effects including lactic acidosis, abdominal pain, diarrheal caused by metformin; hypoglycaemia, weight gain, jaundice, hepatitis and cardiac side effects caused by

sulfonylureas drugs; water retention, peripheral edema and increased fracture risks caused by pioglitazone; in addition to the bloating caused by acarbose [12,39,40]. Moreover, metformin and acarbose are used cautiously in renal impaired patients while thiazolidinediones are contraindicated in cardiac disease patients [41,42]. Insulin may have different side effects including increased lipid reserves, weight gain, lipoatrophy, and hypoglycemic coma [43].

Medicinal plants

The conventional treatment of diabetes involves a sustained reduction of homeostatic blood glucose levels using different drugs, such as metformin, sulfonylurea and thiazolidinediones [44]. However, these synthetic drugs do not adequately inhibit the development of the associated complications, not easily accessible and not affordable by the majority of people in developing countries and furthermore, they may cause a plethora of side effects. Hence, there is a demand for potential alternative therapies to manage diabetes mellitus and its associated complications [12,44].

Since eons of time, the medicinal plants did represent the core of traditional medicines that have been practiced a long time ago in folk medicine and are easily available as a source of treatment all over the world [45]. At present, numerous medicines owe their basis to these medicinal plants since they were defined as plants having comparable properties as synthetic pharmaceutical medicines. The oldest evidence on paper about the use of medicinal plants for making drugs was discovered and dated back in Nagpur, about 5000 years ago [46]. Research has demonstrated that the medicinal plants were still used as traditional medicine to treat fever and malaria worldwide [47-49].

Thus, the science of medicine now gives logical emphasis to the use of medicinal plants in the state of the art for the treatment of chronic diseases like diabetes. There are also various medicinal plants that help people in lowering their high blood sugar levels [50]. *Avicennia marina, Allium cepa, Ficus benghalensis, Rhizophora mucronata, Allium sativum, Pterocarpus marsupium and Gymnema sylvestre*, were studied for their active hypoglycemic properties [51]. These plants also have shown a direct effect on the pancreas and able to enhance insulin blood level [52]. They improve the function of the pancreas by increasing the insulin secretion or reducing the absorption of glucose in the intestine [15]. Medicinal plants also help to maintain the optimum enzymatic reactions in the body therefore, facilitating effective breakdown and synthesis of glucose.

Moreover, medicinal plants contain high levels of saponins, flavonoids, carotenoids, glycosides, antioxidants, terpenoids, and alkaloids needed in the human body. Aside from the anti-diabetic effects of medicinal plants, they also help the body to perform essential metabolic functioning [53]. Considerable scientific research evidence suggests that under oxidative stress situations, reactive oxygen species (ROS) are produced albeit, it is believed that the equilibrium between the oxidation and antioxidation processes results in causing human diseases including diabetes [54]. Since medicinal plants are natural sources, they have fewer side effects, and they offer evidence for the synthesis of novel and improved medicines for the treatment of diabetes [55].

Selected Saudi medicinal plants used for the control of diabetes

It is worthy to note that there are many Saudi medicinal herbs used by healers and herbalist folklore medicine in the treatment of diabetes. The majority of these medicinal plants have not been adequately studied. Moreover, their mechanism of action is not thoroughly understood. The objective of this review focuses on the selected Saudi medicinal plants that are potentially and scientifically validated.

Avicennia marina

Avicennia marina is a member of *Avicenniacea* family that belongs to the genus *Avicennia* [56] which is known as "Grey mangrove". In Saudi Arabia, *A. marina* is widely omnipresent along the Central Red Sea coast where it forms one of the dominant varieties of mangrove [57]. Traditionally, *A. marina* was used for the treatment of ulcer, small pox lesions and snake bites in folk medicine [58]. It was also used to treat scabies and other skin problems besides, its wood is utilised for house building, charcoal production, furniture making, firewood and construction of the sailing boats. Moreover, its branches can be used as stakes for hedges [58].

Avicennia marina contains saponins as phytoconstituents and can activate catalase (CAT) while its antidiabetic effects include β-cells stimulation to release insulin [59]. Rahbaria., *et al* [60]. studied the *A. marina* effects on hormonal profile of diabetic rat's and found a protective effect of this plant. The author concluded

that the use of *A. marina* might prove to be effective in alleviating hormonal imbalances and damage to ovarian tissue in patients suffering from diabetes [60].

Rhizophora mucronata

Rhizophora mucronata is a wind-pollinated tree with potential antidiabetic properties. It is also identified as "red mangrove," and it belongs to *Rhizophoraceae* family. It grows on the tidal creeks banks, on low coastal regions in estuaries and overflowed by usual every day high tides [61]. In Saudi Arabia, it is widely distributed along the Red Sea coast where organic substances are conveyed from the Gulf waters and shore of the Red Sea, between Jizan in the south and Dibain in the north [62]. *R. mucronata* provides fuel and charcoal and it is used for firewood. Previously, it was used to treat haematoma, ulcer, hepatitis, elephantiasis, and diarrhoea. It also possesses antiplasmodial, antioxidant, anti-human immunodeficiency virus (HIV), and hepatoprotective [63-65].

Sur., *et al*. [54] have studied *R. mucronata* for its antidiabetic as well as its antiradical properties and concluded that it did exhibit a strong antioxidants and antidiabetic properties since it helps improve the high blood glucose levels via its antiradical activity. Pandey., *et al*. [65] have also reported about the hypoglycemic effects of leaves of *R. mucronata* in the management of diabetes. In a similar study Haque., *et al*. [66] observed a considerable decrease of postprandial hyperglycemia following sugar intake by this plant's bark. Similarly, Hardoko., *et al*. [67] and Ramu and Vijayakumar [68] documented its antidiabetic effects.

Balanites aegyptiaca

Balanites aegyptiaca is a widespread terrestrial tree that thrive in most tropical and subtropical regions of the world. It is familiar as *Balanitaceea* [69]. The tree plant is widely used by traditional healers in rural areas of many countries [70-75]. In Saudi Arabia, *Balanites aegyptiaca* is cultivated in the western region of Hejaz to the border of Yemen [76]. It is also cultivated in King Abdulaziz University Experimental Farm at Hada Al-Sham area [77].

Balanites aegyptiaca fruits showed significant hypoglycemic effects in streptozocine-induced hyperglycemia in animals [78]. In Egyptian folk medicine, *Balanites aegyptiaca* is utilized as an oral antidiabetic remedy [75]. Rashad., *et al*. [74] reported that administration of *Balanites aegyptiaca* extract to type 2 DM patients for 2 months produced significant reduction in fasting and postprandial blood sugar levels. Another experimental study reported that *Balanites aegyptiaca* extract has antidiabetic action in type-1 DM [79]. *Balanites aegyptiaca* fruit was proved to provoke a hypoglycemic action against streptozocine-induced DM in rats [80]. Moreover, *Balanites aegyptiaca* fruit (cortex) resulted in a reduction of blood glucose level in streptozocine-induced DM in rats [81]. In another study, Baragob., *et al*. [82] demonstrated that *Balanites aegyptiaca* fruit (kernel) extract showed a significant antidiabetic action in alloxan-induced diabetes in rats.

Momordica charantia

Commonly an orbit grow on surface of the ground plant known as bitter melon, bitter melon, karela, balsam pear, or bitter gourd [83]. It grows widely in tropical areas, including parts of East Africa, Asia, the Caribbean, and South America. It belongs to Cucurbitaceae family, and it is used as food, as well as a medicine. The plant was cultivated in Hofuf oasis, Saudi Arabia for the first time. It grows on sandy soil with low organic matter content and deficient in nitrogen and phosphorus [84]. The roots of *Momordica charantia* are useful in the treatment of eye related diseases, the fruit is used to cure biliousness, blood diseases, anaemia, urinary discharges, asthma, ulcers and bronchitis [85].

Momordica charantia is a popular medical folklore plant used for the treating of diabetes-related conditions amongst the indigenous populations of Asia, South America, India, the Caribbean and East Africa [86,87]. Although, abundant data and hypotheses are available on the hypoglycemic effect of *Momordica charantia* in experimental animal models but the clinical studies in human subjects are sparse [88].

Caralluma russeliana

Caralluma russeliana is widely grown and distributed in Africa, Asia, Southeast Europe, Canary Islands, Arabian Peninsula and South Africa, it is a member of *Apocynaceae* family [89]. In Saudi Arabia it is wildly grown in Taif Governate. The plant extracts possess antidiabetic, anticancer, antioxidant, anti-inflammatory and antimicrobial characteristics [90]. Although, the hypoglycemic effect of several species of *Caralluma* were well documented and confirmed efficiently to treat DM such as *Caralluma attenuate Caralluma, tuberculata, Caralluma sinaica* and *Caralluma edulis* [91,92], However, there are few published data on the antidiabetic effect of Caralluma russeliana.

Olea oleaster

The olive tree *Olea oleaster* belongs to *Oleaceae* family. The plant is used extensively in traditional medicine in Mediterranean and European countries [93]. It has hepatoprotective [94], antimicrobial [95], anti-tumor [96] and antidiabetic effects [97,98]. In Saudi Arabia it grows in Taif, Albaha region [94,99]. Supplementation of *O. oleaster* extract significantly decreased the levels of serum glucose, triglycerides, LDL-C and VLDL- in diabetic rats (Al-Thebaiti and Zari, 2018). In a similar study, Almalki., *et al*. [100]. documented that the leaf extracts of Olea oleaster revealed ahypoglycemic action in STZ-induced diabetic rats.

Bibliography

1. Arun KS., *et al*. "Study of management on comorbid conditions in type-2 diabetes mellitus". *Journal of Cell Science and Mutation* 2 (2018): 12-18.

2. Al-Thobaiti SA and Abu Zeid IM. "Antidiabetic potential of Balanites aegyptiaca kernel, flesh and their combination against streptozotocin-induced hyperglycemia in male rats". *Tropical Journal of Pharmaceutical Research* 18.2 (2019): 263-271.

3. Bommer C., *et al*. "Global economic burden of diabetes in adults: Projections From 2015 to 2030". *Diabetes Care* 41.5 (2018): 963-970.

4. Golden SH. "Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications". *American Journal of Cardiology* 108.3 (2011): B59-B67.

5. Tahergorabi Z and Khazaei M. "Imbalance of angiogenesis in diabetic complications: The mechanisms". *International Journal of Preventive Medicine* 3.12 (2012): 827-838.

6. Khalil H. "Diabetes microvascular complications-A clinical update". *Diabetes and Metabolic Syndrome* 11.1 (2017): S133-S139.

7. Lima VC., *et al*. "Risk factors for diabetic retinopathy: A case control study". *International Journal of Retina Vitreous* 2. 21 (2016): 1-7.

8. Mirhoseini M., *et al*. "A study on the association of diabetic dermopathy with nephropathy and retinopathy in patients with type 2 diabetes mellitus". *Journal of Nephropathology* 5.4 (2016): 139-143.

9. Indu R., *et al*. "Polypharmacy and comorbidity status in the treatment of type 2 diabetic patients attending a tertiary care hospital: An observational and questionnaire-based study". *Perspectives in Clinical Research* 9.3 (2018): 139-144.

10. Narres M., *et al*. "The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: A systematic review". *PLoS One* 11.1 (2016): 1-28.

11. Leon BM and Maddox TM. "Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research". *World Journal of Diabetes* 6.13 (2015): 1246-1258.

12. Chaudhury A., *et al*. "Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management". *Frontiers in Endocrinology* 8.6 (2017): 1-12.

13. Verma S., *et al*. "Diabetes mellitus treatment using herbal drugs". *International Journal of Phytomedicine* 10.1 (2018): 1-10.

14. Elekofehinti OO. "Saponins: Anti-diabetic principles from medicinal plants - A review". *Pathophysiology* 22.2 (2015): 95-103.

15. Kooti W., *et al*. "The role of medicinal plants in the treatment of diabetes: A systematic review". *Electronic Physician* 8.1 (2016): 1832-1842.

16. Prabakaran K and Shanmugavel G. "Antidiabetic activity and phytochemical constituents of syzygium cumini seeds in Puducherry Region, South India". *International Journal of Pharmacognosy and Phytochemical Research* 9.7 (2017): 985-989.

17. Abu Zeid IM., *et al*. "Phytochemical and GC-MS analysis of bioactive compounds from Balanites aegyptiaca". *Acta Scientific Pharmaceutical Sciences* 3.8 (2019): 129-134.

18. Gray JP., *et al*. "Thymoquinone, a bioactive component of Nigella sativa, normaliz-es insulin secretion from pancreatic βcells under glucose overload via regulation of malonyl-CoA". *American Journal of Physiology-Endocrinology and Metabolism* 310.6 (2016): 394-404.

19. Bharti SK., *et al*. "Antidiabetic phytoconstituents and their mode of action on metabolic pathways". *Therapeutic Advances in Endocrinology and Metabolism* 9.3 (2018): 81-100.

20. Ozougwu JC. *et al*. "The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus". *Journal of Physiology and Pathophysiology* 4.4 (2013): 46-57.

21. You WB and Henneberg M. "Type 1 diabetes prevalence increasing globally and regionally: The role of natural selection and life expectancy at birth". *BMJ Open Diabetes Research and Care* 4.1 (2016): 1-7.

22. Baynest HW. "Classification, pathophysiology, diagnosis and management of diabetes mellitus". *Journal of Diabetes and Metabolism* 541 (2015): 1-9.

23. Hattersley AT and Thorens B. "Type 2 diabetes, SGLT2 inhibitors, and glucose secretion". *New England Journal of Medicine* 373.10 (2015): 974-976.

24. Karalliedde J and Gnudi L. "Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease". *Nephrology Dialysis Transplantation* 31.2 (2016): 206-213.

25. Meo SA., *et al*. "Prevalence of type 2 diabetes in the Arab World: Impact of GDP and energy consumption". *European Review for Medical and Pharmacological Sciences* 21.6 (2017): 1303-1312.

26. Zhang J., *et al*. (2018). "Advances in early biomarkers of diabetic nephropathy". *Revista da Associação Médica Brasileira* 64.1 (2018): 85-92.

27. Alotaibi A., *et al*. "Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: An overview". *Journal of Epidemiology and Global Health* 7.4 (2017): 211-218.

28. Alhowaish AK. 2013. "Economic costs of diabetes in Saudi Arabia". *Journal of Family and Community Medicine* 20.1 (2013): 1-7.

29. Florencia A., *et al*. "IDF Diabetes Atlas: Sixth edition". 6th edition. International Diabetes Federation; Basel, Switzerland (2013).

30. Al-Rubeaan K., *et al*. "Prevalence of metabolic syndrome in Saudi Arabia- A cross sectional study". *BMC Endocrine Disorders* 18.1 (2018): 1-9.

31. Robert AA., *et al*. "Type 1 Diabetes mellitus in Saudi Arabia: A soaring epidemic". *International Journal of Pediatrics* 2018 (2018): 1-9.

32. Naeem Z. "Burden of diabetes mellitus in Saudi Arabia". *International Journal of Health Sciences (Qassim)* 9. 3 (2015): 1-2.

33. Ghandoora MM., *et al*. "Type 1 diabetes mellitus among pediatrics and adolescents in Saudi Arabia: A systematic review". *International Journal of Advanced Research* 5.2 (2017): 1352-1358.

34. Sherif S and Sumpio B. "Economic development and diabetes prevalence in MENA countries: Egypt and Saudi Arabia comparison". *World Journal of Diabetes* 6.2 (2015): 304-311.

35. Mahmood FM. "Prevalence and prevention of lifestyle-related diseases in Saudi Arabia". *International Journal of Health Sciences (Qassim)* 12.5 (2018): 1-2.

36. Irons BK and Minze MG. "Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated". *Diabetes, Metabolic Syndrome and Obesity* 7 (2014): 15-24.

37. Kupsal K., *et al*. "Metformin combinatorial therapy for type 2 diabetes mellitus". *Journal of Metabolic Syndrome* 5.210 (2016): 1-8.

38. Marín-Peñalver JJ., *et al*. "Update on the treatment of type 2 diabetes mellitus". *World Journal of Diabetes* 7.17 (2016): 354-395.

39. Kalra S. "Incretin enhancement without hyperinsulinemia: α-glucosidase inhibitors". *Expert Review of Endocrinology and Metabolism* 9.5 (2014): 423-425.

40. Sola D., *et al*. "Sulfonylureas and their use in clinical practice". *Archives of Medical Science* 11.4 (2015): 840-848.

41. Betônico CC., *et al*. "Management of diabetes mellitus in individuals with chronic kidney disease: Therapeutic perspectives and glycemic control". *Clinics (Sao Paulo)* 71.1 (2016): 47-53.

42. Sharma DC., *et al*. "Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure". *Indian Journal of Endocrinology and Metabolism* 21.4 (2017): 618-629.

43. Gumprecht J and Nabrdalik K. "Hypoglycemia in patients with insulin treated diabetes". *Polskie Archiwum Medycyny Wewnętrznej* 126.11 (2016): 870-878.

44. Gengiah K., *et al*. "Antidiabetic antihyperlipidemic and hepatoprotective effect of gluconorm-5: A polyherbal formulation in steptozotocin-induced hyperglycemic rats". *Ancient Science of Life* 34.1 (2014): 23-32.

45. Rakotoarivelo NH., *et al*. "Medicinal plants used to treat the most frequent diseases encountered in Ambalabe rural community, Eastern Madagascar". *Journal of Ethnobiology and Ethnomedicine* 11.68 (2015): 1-16.

46. Petrovska BB. "Historical review of medicinal plants' usage". *Pharmacognosy Reviews* 6.11 (2012): 1-5.

47. Jain R., *et al*. "Avicequinone C isolated from Avicennia marina exhibits 5α-reductase-type 1 inhibitory activity using an androgenic alopeia relevant cell-based assay system". *Molecules* 19.5 (2014): 6809-6821.

48. Madala NE., *et al*. "Development and optimization of an UPLC-QTOF-MS/MS method based on an in-source collision induced dissociation approach for comprehensive discrimination of chlorogenic acids isomers from Momordica plant species". *Journal of Analytical Methods in Chemistry* (2014): 1-7.

49. Ngarivhume T., *et al*. "Medicinal plants used by traditional healers for the treatment of malaria in the chipinge district in Zimbabwe". *Journal of Ethnopharmacology* 15.159 (2015): 224-237.

50. Aljaghthmi O., *et al*. "Bioactive compounds extracted from mangrove plants (Avicennia marina and Rhizophora mucronata): An Overview". *Pathophysiology* (2018): 1- 20.

51. Burnett A., *et al*. "Investigation of the blood glucose lowering potential of the Jamaican Momordica charantia (Cerasee) fruit in Sprague-Dawley Rats". *West Indian Medical Journal* 64.4 (2015): 315-319.

52. Gupta PD and De A. "Diabetes mellitus and its herbal treatment". *International Journal of Research in Pharmaceutical and Biomedical Sciences* 3.2 (2012): 706-721.

53. Afrisham R., *et al*. "Inhibitory effect of Heracleum persicum and Ziziphus jujuba on activity of alpha-amylase". *Journal of Botany* 20 (2015): 1-8.

54. Sur TK., *et al*. "Antiradical and antidiabetic properties of standardized extract of Sunderban mangrove Rhizophora mucronata". *Pharmacognosy Magazine* 11.42 (2015): 389 -394.

55. Giovannini P., *et al*. "Medicinal plants used in the management of diabetes and its sequelae in Central America: A review". *Journal of Ethnopharmacology* 184 (2016): 58-71.

56. Moghaddam FH., *et al*. "Effects of Avicennia marina leaves aqueous and hydro alcoholic extract on streptozotocin-induced diabetic male rats". *Journal of Rafsanjan University of Medical Sciences* (2011): 245-254.

57. Almahasheer H., *et al*. "Phenology and growth dynamics of A. marina in the central Red Sea". *Scientific Reports* 6 (2016): 1-9.

58. Thatoi H., *et al*. "The genus Avicennia, a pioneer group of dominant mangrove plant species with potential medicinal values: A review". *Frontiers in Life Science* 9.4 (2016): 267-291.

59. Babu MB. "Bioactivity of Avicennia marina and Rhizophora mucronata for the management of diabetes mellitus". *World Journal of Pharmaceutical Research* 3.1 (2014): 311-318.

60. Rahbarian R., *et al*. "The effect of aqueous extract of mangrove leaves (Avicennia marina) on pituitary-hormones of gonadal axis and ovarian follicle numbers in diabetic rats". *Armaghanedanesh* 22.1 (2017): 1-17.

61. Ragavan P., *et al*. "Rhizophora mucronata var. Alokii - a new variety of mangrove species from the Andaman and Nicobar Islands, India (Rhizophoraceae)". *PhytoKeys* 52 (2015): 95-103.

62. FAO, "Global forest resources assessment 2005 thematic study on mangroves Saudi Arabia". Forestry Paper. Rome (2005).

63. Ravikumar S., *et al*. "In vitro antiplasmodial activity of ethanolic extracts of mangrove plants from South East coast of India against chloroquine-sensitive Plasmodium falciparum". *Parasitology Research* 108.4 (2011): 873- 878.

64. Ravikumar S. and Gnanadesigan M. "Hepatoprotective and antioxidant properties of Rhizophora mucronata mangrove plant in CCl4 intoxicated rats". *Journal of Experimental and Clinical Medicine* 4.1 (2012): 66-72.

65. Pandey AK., *et al*. "Hypoglycemic effect of Rhizophora mucronata in streptozotocin-induced diabetic rats". *Journal of Complementary and Integrative Medicine* 11.3 (2014): 179-183.

66. Haque M., *et al*. "Revelation of mechanism of action of Rhizophora mucronata Poir. Bark extract forits antidiabetic activity by gut perfusion and six segment method in long evans rats". *International Research Journal of Pharmacy* 4.5 (2013): 111-114.

67. Hardoko SE., *et al*. "Study of ripe Rhizophora mucronata fruit flour as functional food for antidiabetic". *International Food Research Journal* 22.3 (2015): 953-959.

68. Ramu A and Vijayakumar V. "Antidiabetic activity of 7-methoxycoumarin from the bark of marine plant Rhizophora mucronata". *Global Advanced Research Journal of Medicinal Plants* 4.1 (2016): 1-6.

69. Elfeel AA. "Effect of seed pre-treatment and sowing orientation on germination of Balanites aegyptiaca (L.) Del. seeds". *American-Eurasian Journal of Agricultural and Environmental Sciences* 12.7 (2012): 897-900.

70. Dwivedi A., *et al*. "Anthelmintic activity of root bark of Balanites aegyptiaca (L.) Del". *Ethnobotanical Leaflets* 13 (2009): 564-567.

71. Jagtap SD., *et al*. "Traditional ethnomedicinal knowledge confined to the Pawra tribe of Satpura hills, Maharashtra, India". *Ethnobotanical Leaflets* 13 (2009): 98-115.

72. Vijigiri D and Sharma PP. "Traditional uses of plants in indigenous folklore of Nizamabad district, Andhra Pradesh, India". *Ethnobotanical Leaflets* 14 (2010): 29-45.

73. Chothani DL and Vaghasiya HU. "A review on Balanites aegyptiaca Del (desert date): Phytochemical constituents, traditional uses, and pharmacological activity". *Pharmacognosy Reviews* 5.9 (2011): 55-62.

74. Rashad H., *et al*. "Randomized double-blinded pilot clinical study of the antidiabetic activity of Balanites aegyptiaca and UPLC-ESI-MS/MS identification of its metabolites". *Pharmaceutical Biology* 55.1 (2017): 1954-1961.

75. Singh AP., *et al*. "A prespective review on a novel plant Balanites aegyptiaca (linn.)". *Journal of Pharmaceutical and Biological Sciences* 5.6 (2017): 273-277.

76. Al-Asmari AK., *et al*. "A review of hepatoprotective plants used in Saudi traditional medicine". *Evidence-Based Complementary and Alternative Medicine* 2014 (2014): 1-22.

77. Elfeel AA and Abohassan RA. "Response of Balanites aegyptiaca (L.) Del. Var. Aegyptiaca seedlings from three different sources to water and salinity stresses". *Pakistan Journal of Botany Bot* (2015): 1199-1206.

78. Ghanem KZ., *et al*. "The effect of herbal tea from Balanites aegyptiaca fruits on streptozotocin-induced diabetes mellitus in rats". *International Journal of PharmTech Research* 9.10 (2016): 8-15.

79. Abou Khalil NS., *et al*. "Antidiabetic and antioxidant impacts of desert Date (Balanites aegyptiaca) and Parsley (Petroselinum sativum) aqueous extracts: Lessons from experimental rats". *Journal of Diabetes Research* (2016): 1-10.

80. Al-Malki AL., *et al*. "Management of hyperglycaemia by ethyl acetate extract of Balanites aegyptiaca (Desert Date)". *Molecules (Basel, Switzerland)* 20.8 (2015): 14425-14434.

81. Qusti SY., *et al*. "Role of Balanites aegyptiaca in attenuation of diabetic nephropathy". *International Journal of Life Sciences Research* 3.4 (2015): 8-14.

82. Baragob AE., *et al*. "The hypoglycemic effect of the aqueous extract of the fruits of Balanites aegypticea in alloxan-induced diabetic rats". *Pharmacognosy Research* 6.1 (2014): 1-5.

83. Joseph B and Jini D. "Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency". *Asian Pacific Journal of Tropical Disease* 3.2 (2013): 93-102.

84. Almarzooq MA and Moussa EA. "Hypoglycaemic effect of momordica charantia (Karela) in normal and alloxan diabetic Albino mice". *Egyptian Journal of Experimental Biology (Zoology)* 5 (2009): 487 - 493.

85. Kumar KP and Bhowmik D. "Traditional medicinal uses and therapeutic benefits of momordica charantia Inn". *International Journal of Pharmaceutical Sciences Review and Research* 4.3 (2010): 23-28.

86. Cefalu WT., *et al*. "Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans". *Endocrine, Metabolic and Immune Disorders - Drug Targets* 8.2 (2008): 78-81.

87. Cousens G. "There is a cure for diabetes: The tree of life 21day program". California: North Atlantic Books (2008):191-192.

88. Chanda R., *et al*. "Anti-diabetic Activity of Momordica charantia or Bitter Melon: A Review". *Acta Scientific Pharmaceutical Sciences* 3.5 (2019): 24-30.

89. Meve U and Liede S. "Subtribal Division of Ceropegieae (Apocynaceae-Asclepiadoideae)". *Taxon* 53.1 (2004): 61-72.

90. Zari TA and Al-Thebaiti MA. "Effects of Caralluma russeliana stem extract on some physiological parameters in streptozotocininduced diabetic male rats". *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*11 (2018): 619-631.

91. Wadood AB., *et al*. "Effects of Acacia arabica and Caralluma edulis on blood glucose levels of normal and alloxan diabetic rabbits". *Journal of Pakistan Medical Association* 39.8 (1989): 208-212.

92. Ali H., *et al*. "Ethnobotanical profile of some plant resources in Malam Jabba valley of Swat, Pakistan". *Journal of Medicinal Plants Research* 5.18 (2011): 4676-4687.

93. Abd El-Rahman HSM. "The effect of olive leaf extract and -Tocopherol on nephroprotective activity in rats". *Journal of Nutrition and Food Sciences* 6.2 (2016): 1-9.

94. Al-Attar A M., *et al*. "Effect of Olea oleaster and Juniperus procera leaves extracts on thioacetamide induced hepatic cirrhosis in male albino mice". *Saudi Journal of Biological Sciences* 23.3 (2016): 363-371.

95. Lee OH and Lee BY. "Antioxidant and antimicrobial activities of individual and combined phenolics in Olea europaea leaf extract". *Bioresource Technology*101.10 (2010): 3751-3754.

96. Grawish ME., *et al*. "Inhibition of 4-NQO-induced F433 rat tongue carcinogenesis by oleuropein-rich extract". *Medical Oncology* 28.4 (2011): 1163-1168.

97. Jemai H., *et al*. "Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats". *Journal of Agricultural and Food Chemistry* 57.19 (2009): 8798-8804.

98. Wainstein J., *et al*., "Olive leaf extract as a hypoglycemic agent in both human diabetic subjects and in rats". *Journal of Medicinal Food* 15.7 (2012): 605-610.

99. Al-Thebaiti MAM and Zari TA. "Influence of Olea oleaster leaves extract on some physiological parameters in streptozotocin-induced diabetic rats". *World Applied Sciences Journal* 36.1 (2018): 16-28.

100. Almalki D.., *et al*. "Comparative study on the influence of some medicinal plants on diabetes induced by streptozotocin in male rats". *BioMed Research International* (2019): 1-11.

Volume 3 Issue 10 October 2019